Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2013-12-10 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于下属公司完成工商注册登记的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of business registration for a subsidiary company. It includes details about the subsidiary's name, legal representative, registered capital, and business scope. There is no financial data, no mention of a report being attached or published, and no indication of a meeting or voting results. The document is a regulatory announcement about corporate registration and investment changes, which fits best under general regulatory filings rather than a specific financial report or meeting material.
2013-12-10 Chinese
非公开发行股票之发行过程和认购对象合规性的专项法律意见
Capital/Financing Update Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the compliance of a non-public stock issuance process and the qualifications of the subscription parties for Zhongyuan Xiehe Stem Cell Bioengineering Co., Ltd. It references specific approvals, authorizations, and regulatory compliance related to a non-public issuance of A-shares. The document includes detailed legal analysis, verification of subscription contracts, and capital verification reports. It is not a financial report, earnings release, or management discussion, but a specialized legal opinion related to capital issuance. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is about 4782 characters, which is sufficient to be the actual legal opinion rather than a brief announcement. Therefore, the correct classification is CAP with high confidence.
2013-12-09 Chinese
非公开发行股票发行情况报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "非公开发行股票发行情况报告书" which translates to "Non-public Issuance of Shares Issuance Report." It details the procedures, approvals, share issuance quantities, pricing, subscription, and changes in shareholder structure related to a non-public stock issuance by the company. It includes information about the underwriting, legal opinions, and regulatory approvals. The content focuses on capital raising through a non-public share issuance, including the use of proceeds and impact on shareholding and capital structure. This matches the definition of a Capital/Financing Update (CAP), which covers company fundraising and capital structure changes. The document is substantive and not merely an announcement or a certification, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2013-12-09 Chinese
非公开发行股票发行过程和认购对象的合规性报告
Capital/Financing Update Classification · 95% confidence The document is a detailed compliance report from a securities company (宏源证券股份有限公司) regarding a non-public stock issuance by 中源协和干细胞生物工程股份公司. It includes specifics about the issuance price, quantity, approval process, subscription details, and verification by an accounting firm. The document is not a brief announcement but a substantive report on the issuance process and compliance with regulatory requirements. It does not contain financial statements or quarterly/yearly financial results, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a simple announcement of a report publication, nor is it a certification letter. The content focuses on the capital raising activity and compliance related to a non-public stock issuance, which fits the Capital/Financing Update (CAP) category.
2013-12-09 Chinese
非公开发行股票发行结果暨股本变动公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a non-public issuance of shares by the company 中源协和干细胞生物工程股份公司. It includes information about the number of shares issued, pricing, issuance process, approvals by the board and shareholders, regulatory approvals by the China Securities Regulatory Commission, details about the subscriber (a controlling shareholder), changes in shareholding structure before and after the issuance, and the use of proceeds. The document also contains legal and audit opinions related to the issuance. The content focuses on the issuance results and changes in capital structure rather than a full financial report or earnings announcement. This matches the definition of a Capital/Financing Update (CAP), which covers company fundraising and capital structure changes. The document length is over 6,000 characters and contains substantive details, so it is not a mere announcement of a report (RPA) or a regulatory filing (RNS). Therefore, the correct classification is CAP with high confidence.
2013-12-09 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding of Tianjin Development Zone Deyuan Investment Development Co., Ltd. in Zhongyuan Xiehe Stem Cell Bioengineering Co., Ltd., including the number of shares held before and after the transaction, the method of equity change (cash subscription of non-publicly issued shares), and the intention to possibly increase holdings in the future. It also includes legal declarations and compliance with securities laws. The document is a formal notification of a change in significant share ownership levels, consistent with a Major Shareholding Notification filing. It is not an annual report, earnings release, or other financial report, nor is it a proxy, call transcript, or management report. The length and content confirm it is a full report of shareholding change, not just an announcement of a report publication or a certification. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2013-12-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.